New drug combinations
AssigneePharmacia & Upjohn Company
InventorDuncan Paul Taylor
Life of this patent
Estimating the term…
Abstract
This patent application describes, a new combination treatment of selective, noradrenaline-reuptake inhibitors (NARI) and specifically, reboxetine, and pindolol to provide rapid relief to patients suffering from depression, general anxiety, attention deficit hyperactivity disorder (ADHD), anxiety disorders such as obsessive compulsive disorders (OCD), panic disorders (PD), social phobia (SD) and the like.
Claims21
A single dosage form of reboxetine and pindolol.
A method of treating a patient experiencing symptoms selected from;
- depression, general anxiety disorders (GADs), Addictive Disorders, attention deficit hyperactivity disorder (ADHD), and anxiety disorders such as obsessive compulsive disorder (OCD), panic disorder (PD), social phobia (SP), comprising the administration of a therapeutically effective, nontoxic dose of pindolol, its derivatives and or pharmaceutically acceptable salts thereof to a patient and administering a therapeutically effective, nontoxic dose of a selective, a noradrenaline reuptake inhibitor (NARI), its derivatives and or pharmaceutically acceptable salts thereof to a patient.
The use of reboxetine and pindolol, their derivatives and or pharmaceutically acceptable salts thereof in the manufacture of a medicament comprising an effective, nontoxic dose of reboxetine and pindolol to treat general anxiety disorders (GADs), Addictive Disorders, attention deficit hyperactivity disorder (ADHD), and anxiety disorders such as obsessive compulsive disorder (OCD), panic disorder (PD), social phobia (SP), and/or for the treatment of any of the symptoms of those diseases.
Dependencies are inferred from the claim text.